絞り込み

16639

広告

Cost-effectiveness of apixaban compared to other anticoagulants in patients with atrial fibrillation in the real-world and trial settings.

著者 de Jong LA , Groeneveld J , Stevanovic J , Rila H , Tieleman RG , Huisman MV , Postma MJ , van Hulst M
PLoS One.2019 ; 14(9):e0222658.
この記事をPubMed上で見るPubMedで表示
この記事をGoogle翻訳上で見る Google翻訳で開く

スターを付ける スターを付ける     (32view , 0users)

Full Text Sources

Randomized clinical trials (RCTs) and real-world data (RWD) in patients with atrial fibrillation have shown that-compared to vitamin K antagonists (VKAs)-non-VKA oral anticoagulants (NOACs) are at least as effective in the prevention of ischaemic stroke, while decreasing the risk of bleeding.
PMID: 31527894 [PubMed - in process]
印刷用ページを開く Endnote用テキストダウンロード